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ABSTRACT: A mild and selective photocatalytic C-H 18F-fluorination reaction has been developed that provides direct access to 18F-fluorinated amino acids. The biodis-tribution and uptake of three 18F-labelled leucine ana-logues via LAT1 mediated transport in several cancer cell lines is reported. PET imaging of mice bearing PC3 (pros-tate) or U87 (glioma) xenografts using 5-[18F]-fluoro-homoleucine showed high tumor uptake and excellent tumor visualization, highlighting the utility of this strat-egy for rapid tracer discovery for oncology.  
Positron emission tomography (PET) uses radioi-sotopes to interrogate specific physiological processes in real time and in living systems.1 Thus, PET is ideally suited for the early detection of tumors and metasta-ses, and is an established modality for diagnosis, stag-ing, and treatment planning of various malignan-cies.2,3 The selective imaging of cancers with PET often exploits radiotracers that target aberrant cellular me-tabolism or increased protein expression.4 For exam-ple, the widely used cancer diagnostic 2-deoxy-2-[18F]fluoro-D-glucose4,5 ([18F]FDG (1), Figure 1) takes advantage of the increased glucose up-          
Figure 1. Radiotracers for PET imaging in oncology and 18F-labeled analogues of leucine.  
take and glycolysis in many tumors. Increased amino acid (AA) uptake through over-expression of AA trans-porters is also a signature feature in cancers, and radi-olabeled AAs (e.g., 26 and 37) are highly sought as im-aging agents.2,3,8 The uptake of AAs by L-type AA transporters (LATs)9 is a particularly appealing target for PET radiotracers. Most notably, the LAT1 isoform transports branched and aromatic AAs, and is highly upregulated in several cancers (e.g., prostate, breast and brain) and at metastatic sites.9a Among the wide range of AAs transported by LAT1, leucine plays a uniquely important role in cancer biol-ogy as large cellular concentrations of leucine are re-quired to trigger mTORC1 activation and support ac-celerated protein synthesis.10 Not surprisingly then, L-1-[11C]leucine represents a promising PET imaging agent.11 Unfortunately, its widespread use is limited by a reliance on the rapidly decaying radionuclide 11C (t½ = 20.4 min), which restricts use to PET clinics with on-site cyclotron facilities. The longer lived radionu-clide 18F (t½ = 109.8 min) is incorporated in the leucine mimic [18F]FACBC (4),12 which was recently approved by the US FDA for recurrent prostate cancer imag-ing.12a Recently, the boramino acid [18F]Leu-BF3 (5) was also reported,13 adding to the repertoire of radio-labeled leucine mimics. Notwithstanding these and other advances,8 there is no general synthetic strategy to effect selective 18F-labeling of AAs such as leucine without significantly altering the parent structure or relying on prosthetic groups. Here, we describe the di-rect radiofluorination14 of unprotected, branched ali-phatic amino acids. The PET imaging of mice bearing subcutaneous PC3 or U87 xenografts using a new 18F-labeled analogue of leucine highlights the potential for this convenient reaction to rapidly access amino acid-derived imaging agents for cancer. 
 Figure 2. Decatungstate-catalyzed C-H fluorination applied to the production of 4-[18F]fluoroleucine (4-[18F]FL (7)).   We recently reported the decatungstate-catalyzed fluorination of unactivated C-H bonds,15a and have ap-plied this strategy to the selective fluorination of ali-phatic15a,15b and benzylic15c C-H bonds. This reaction involves hydrogen atom abstraction by a photoacti-vated decatungstate catalyst16 followed by fluorine atom transfer17 from N-fluorobenzene-sulfonimide (NFSI) to the resultant carbon radical (e.g. 8, Figure 2). Considering the high degree of selectivity observed for C-H fluorination at the branched position in esters of leucine15b and valine,15a we contemplated develop-ment of the photocatalytic C-H 18F-fluorination reac-tion depicted in Figure 2 using [18F]NFSI,18 a reagent that has been developed by Gouverneur and Luthra.18,19 This unique process would provide direct access to 4-[18F]FL (7)20 or other radiolabeled AA sub-strates for LAT1 from readily available or natural AAs (e.g., 6).   We began by exploring the fluorination of L-leu-cine·HCl using conditions previously reported by us for the large scale (~50 g) non-radioactive synthesis of 4-fluoroleucine methyl ester.15b We were pleased to discover that this mild process is also compatible with direct fluorination of the unprotected amino acid, and that 4-FL could be produced in modest yield (~20%) after 1 h. Several reactor configurations (batch and flow) were evaluated and ultimately, a narrow-bore PTFE tube wrapped around a BLB lamp21 proved opti-mal, with ~60% conversion to 4-FL observed after only 40 min. While separable by HPLC,21 the removal of leucine from 4-FL was ultimately deemed unneces-sary as plasma concentrations of leucine range from 100-150 μM,22 making it unlikely that residual leucine would interfere with the pharmacokinetic perfor-mance of the tracer. It was eventually found that a strong cation exchange resin retained the 4FL/leucine mixture and not NFSI, NHSI or other reaction by-prod-ucts, and that the purified AA mixture could then be rapidly eluted using aqueous base (without require-ment for HPLC). 
The synthesis of [18F]NFSI was accomplished using a modified version of the reaction reported by Luthra and Gouverneur.18 For our purposes,23 a 5-10 min cy-clotron irradiation of [18O]O2 produced [18F]F2 gas24 from which ~1.5 GBq was trapped in the NaN(SO2Ph)2 
→ [18F]NFSI reaction mixture. Rapid (<5 min) purifi-cation of [18F]NFSI using a C18 SepPak afforded a so-lution of [18F]NFSI (0.2-0.5 GBq) in H2O-CH3CN with an impurity profile similar to that reported previ-ously.18,21 Critically, this modified process avoids the drying of [18F]NFSI by azeotropic distillation (110 °C, 20 min) required for other uses of this reagent.18 The optimized photocatalytic C-H 18F-fluorination of L-leucine then simply involved adding the H2O-CH3CN solution of [18F]NFSI to a slurry of NaDT and L-leu-cine·HCl in H2O. This mixture was irradiated for 40 min and purified as described for 4-FL above (Table 1). The specific activity for the 4-[18F]FL thus pro-duced was ~7 MBq/µmol,23 and the radiochemical pu-rity of this material was >97%. The radiochemical yield for isolated and purified 4-[18F]FL (from [18F]NFSI) is 23±3.3% (n = 4, decay corrected) with a radiosynthesis time of 50 min. Repetition of this reac-tion using DL-leucine provided (±)-4-[18F]FL and al-lowed us to confirm by chiral HPLC that no racemiza-tion occurred during radiofluorination.21 It is notable that while this method uses low specific activity (SA) [18F]F2 gas (~1 GBq µmol-1),18 which may not be suit-able for many purposes, clinically relevant doses of several amino acid radiotracers have been manufac-tured via this process.19c,25 We next examined the uptake of 4-[18F]FL in cancer cell lines LNCaP, PC3 and MCF7 showing various ex-pression levels of LAT1. Notably, there was significant uptake in MCF7 cells, lower uptake in PC3 cells and al-most no uptake in LNCaP cells,21 which mirrors the ex-pected LAT1 mRNA expression levels (RMA log2) in these cell lines of 13.05 (MCF7), 10.40 (PC3) and 6.49 (LNCaP).26 The uptake of 4-[18F]FL in both PC3 and MCF7 cells was also significantly blocked by the addi-tion of 2-amino-2-norbornanecarboxylic acid (BCH), a LAT1 inhibitor,27 suggesting that LAT1 is largely re-sponsible for their 4-[18F]FL uptake. However, analysis of the biodistribution of 4-[18F]FL in healthy mice showed high bone accumulation (Figure 4), which is indicative of in vivo defluorination of the radiotracer and an obvious barrier to its further clinical develop-ment. The in vivo defluorination of 4-[18F]FL is consistent with the propensity for this molecule to undergo γ-lac-tone formation, liberating fluoride.28 As rate of lactone formation is strongly influenced by ring size,29 we con-templated the radiosynthesis of 5-[18F]fluoro-homoleucine (5-[18F]FHL (8)), 5-[18F]fluoro-β-amino-homoleucine (5-[18F]FBAHL (9)), 3-[18F]fluorovaline 
 (3-[18F]FV (10)), and 3-[18F]fluoroisoleucine (3-[18F]FI (11)).30 It was expected that defluorination of these amino acids via β- or δ-lactone formation would be greatly attenuated. Moreover, in addition to trans-porting branched aliphatic and aromatic amino acids, a recent report by Kanai31 highlighted the efficient transport of homoleucine and β-aminohomoleucine by LAT1 in HeLA S3 cells. As summarized in Table 1, 5-[18F]FHL (8) and 5-[18F]FBAHL (9) could be readily prepared and purified without modification to the process established for 4-[18F]FL.21 The radiofluorina-tion of valine and isoleucine afforded 3-[18F]FV (10) and mixtures of 3- and 4-[18F]FI (e.g., 11) albeit in lower RCY owing to decreased rate of these reactions, which is consistent with our earlier findings from the fluorination of aliphatic esters.15a The biodistribution of both 8 and 9 was examined in healthy mice (Figure 3) and we were delighted to find that neither of these radiotracers showed any appreciable accumulation of activity in the bone at 60 min post injection (PI). The uptake of 5-[18F]FHL (8) was also examined in a panel of LAT1-expressing cancer cell lines that included LNCaP, PC3, MCF7 and U87 (glioma).21 Again, uptake in these cancer cell lines correlated well with their ex-pected mRNA expression levels for LAT126 and was substantially blocked by addition of the LAT1 inhibitor BCH,27 suggesting that transport of this radiotracer is significantly mediated by LAT1. The uptake of 5-[18F]FHL (8) in several cancer cell lines and its improved biodistribution over 4-[18F]FL inspired us to undertake an imaging study using this tracer in mice bearing human glioma (U87) or pros-tate cancer (PC3) xenografts. Biodistribution studies indicated high tumor accumulation (5.9±0.7 %ID/g  (n=4) for U87, 5.6±3.2 %ID/g (n=5) for PC3 at 60 min pi) of 5-[18F]FHL was observed with both U87 and PC3 xenografts.21 Combined with low background uptake, 5-[18F]FHL provided excellent tumor visualization and 
high tumor contrast ratios as ev-idenced in Figure 4.21 Excretion of 5-[18F]FHL occurred predom-inantly by renal clearance, with accumulation observed in the pancreas, kidneys and bladder. Tissue time activity curves21 ob-tained in selected organs using dynamic images showed rapid accumulation of 5-[18F]FHL in the tumors and pancreas, peak-ing shortly before 10 minutes, followed by slow efflux. Low up-take was observed in muscles and bone, further evincing the improved in vivo stability of 5-[18F]FHL over the L-leucine de-rivative 4-[18F]HL. 
Figure 3. Biodistribution at 60 min pi of 4-[18F]FL (7), 5-[18F]FHL (8) and 5-[18F]FBAHL (9) in healthy mice.  In summary, we have developed a mild 18F-labeling strategy that selectively replaces the tertiary C-H bond in branched aliphatic amino acids with a C-18F bond. Importantly, this process obviates both complicated precursor synthesis and the use of prosthetic groups. The uptake of both 4-[18F]FL and 5-[18F]FHL in several cancer cell lines was investigated and found to corre-late well with LAT1 expression, highlighting their po-tential as metabolic PET imaging agents. However, the biodistribution of these two radiotracers differed sig-nificantly, with 4-[18F]FL displaying high bone uptake suggestive of in vivo defluorination. The imaging abil-ity of 5-[18F]FHL was examined in mice bearing hu-man glioma and prostate cancer xenografts and high accumulation was found in the tumors, which pro-vided excellent tumor visualization and no significant defluorination was observed. Notably, this convenient radiofluorination should enable rapid proof-of-feasi-bility studies on a variety of related amino acids and biomolecules and support high throughput produc-tion of radiotracers. 
Table 1. 18F-Fluorination of unprotected branched aliphatic amino acids.a 
 Figure 4. PET imaging of 5-[18F]FHL in mice bearing human glioma (U87) xenografts. Maximum intensity projection im-ages overlaid on CT (a) and standalone PET images (b) of the biodistribution of 5-[18F]FHL at 60 min show high accu-mulation of 5-[18F]FHL in the tumor (red arrow). 
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